Literature DB >> 22884356

Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer.

Steve Schoonooghe1, Damya Laoui, Jo A Van Ginderachter, Nick Devoogdt, Tony Lahoutte, Patrick De Baetselier, Geert Raes.   

Abstract

In vivo imaging technology holds promise for refined monitoring of inflammation, both in the clinic and in preclinical animal models, with applications including improved diagnosis, prognosis and therapy monitoring. In particular, molecular imaging, aimed at non-invasively studying molecular and cellular processes in intact organisms, can hereby not only provide information about the amount of inflammation, but also on the type of inflammation and on cells and/or receptors involved. Hereto, an important requisite is the availability of the proper biomarkers and specific probes for targeting these biomarkers. In the current review, we focus on a number of markers on inflamed endothelium and infiltrating myeloid cells (including macrophages) as interesting targets for tracking inflammatory reactions and argue that such markers are not only useful in case of inflammatory diseases of infectious or autoimmune origin, but also for monitoring cancer evolution through the associated inflammation. We elaborate on nanobodies as innovative, specific probes to target these inflammation-associated markers for in vivo molecular imaging.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884356     DOI: 10.1016/j.imbio.2012.07.009

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  20 in total

1.  Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.

Authors:  M Lemaire; M D'Huyvetter; T Lahoutte; E Van Valckenborgh; E Menu; E De Bruyne; P Kronenberger; U Wernery; S Muyldermans; N Devoogdt; K Vanderkerken
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

2.  Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

Authors:  Sabrina Rizzolio; Gabriella Cagnoni; Chiara Battistini; Stefano Bonelli; Claudio Isella; Jo A Van Ginderachter; René Bernards; Federica Di Nicolantonio; Silvia Giordano; Luca Tamagnone
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

Review 3.  In vivo imaging with antibodies and engineered fragments.

Authors:  Amanda C Freise; Anna M Wu
Journal:  Mol Immunol       Date:  2015-04-28       Impact factor: 4.407

4.  Evaluation of Nanobody Conjugates and Protein Fusions as Bioanalytical Reagents.

Authors:  Virginia J Bruce; Brian R McNaughton
Journal:  Anal Chem       Date:  2017-03-20       Impact factor: 6.986

Review 5.  A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics.

Authors:  Shengping Qin; Brett Z Fite; M Karen J Gagnon; Jai W Seo; Fitz-Roy Curry; Frits Thorsen; Katherine W Ferrara
Journal:  Ann Biomed Eng       Date:  2013-09-10       Impact factor: 3.934

6.  New applications of nanotechnology for neuroimaging.

Authors:  G Suffredini; J E East; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-28       Impact factor: 3.825

7.  Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis.

Authors:  Fang Zheng; Amanda Sparkes; Patrick De Baetselier; Steve Schoonooghe; Benoit Stijlemans; Serge Muyldermans; Véronique Flamand; Jo A Van Ginderachter; Nick Devoogdt; Geert Raes; Alain Beschin
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

8.  Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW.

Authors:  Abolfazl Amini; Yaghoub Safdari; Fatemeh Tash Shamsabadi
Journal:  Mol Imaging       Date:  2022-04-14       Impact factor: 3.250

9.  Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging.

Authors:  Xiaozhou Fan; Luofu Wang; Yanli Guo; Zhui Tu; Lang Li; Haipeng Tong; Yang Xu; Rui Li; Kejing Fang
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

Review 10.  Nanobodies: new avenue to treat kidney disease.

Authors:  Nicola Wanner; Thomas Eden; Nastassia Liaukouskaya; Friedrich Koch-Nolte
Journal:  Cell Tissue Res       Date:  2021-06-16       Impact factor: 4.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.